CellOrigin Biotech Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 8

CellOrigin Biotech General Information

Description

Developer of immune cell therapies designed for the treatment of solid tumors and hematological malignancies. The company utilizes single-cell sequencing, synthetic biology, and gene editing to develop chimeric antigen receptor macrophages and natural killer cells, enabling healthcare providers to access off-the-shelf allogeneic treatments that infiltrate the tumor microenvironment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 201 East, Building 4, Number 110 Liuze Street, Cangqian Subdistrict
  • Yuhang District
  • Hangzhou, Zhejiang 311121
  • China
+86 153
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 201 East, Building 4, Number 110 Liuze Street, Cangqian Subdistrict
  • Yuhang District
  • Hangzhou, Zhejiang 311121
  • China
+86 153

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CellOrigin Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 20-Sep-2023 Completed Generating Revenue
4. Early Stage VC 16-Feb-2022 Completed Generating Revenue
3. Early Stage VC 16-Jul-2021 Completed Generating Revenue
2. Early Stage VC 06-Feb-2021 Completed Generating Revenue
1. Seed Round 28-Apr-2019 Completed Startup
To view CellOrigin Biotech’s complete valuation and funding history, request access »

CellOrigin Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellOrigin Biotech Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Goldport Capital Venture Capital Minority
Hangzhou Yuhang State-owned Capital Investment and Operation Group Government Minority
Jifeng Ventures Venture Capital Minority
Shenzhen Yifeng Investment Management Enterprise Venture Capital Minority
Yinxinggu Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

CellOrigin Biotech FAQs

  • When was CellOrigin Biotech founded?

    CellOrigin Biotech was founded in 2018.

  • Where is CellOrigin Biotech headquartered?

    CellOrigin Biotech is headquartered in Hangzhou, China.

  • What is the size of CellOrigin Biotech?

    CellOrigin Biotech has 1 total employees.

  • What industry is CellOrigin Biotech in?

    CellOrigin Biotech’s primary industry is Drug Discovery.

  • Is CellOrigin Biotech a private or public company?

    CellOrigin Biotech is a Private company.

  • What is CellOrigin Biotech’s current revenue?

    The current revenue for CellOrigin Biotech is .

  • How much funding has CellOrigin Biotech raised over time?

    CellOrigin Biotech has raised $15.7M.

  • Who are CellOrigin Biotech’s investors?

    Goldport Capital, Hangzhou Yuhang State-owned Capital Investment and Operation Group, Jifeng Ventures, Shenzhen Yifeng Investment Management Enterprise, and Yinxinggu Capital are 5 of 8 investors who have invested in CellOrigin Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process